The anti-obesity drug market encompasses drugs that help in weight loss by decreasing appetite or increasing fullness. These drugs work by affecting the centers in the brain that control appetite and satiety. The widely used anti-obesity drugs are Orlistat, Lorcaserin, Phentermine+Topiramate, and Liraglutide. The anti-obesity drug space is gaining huge traction due to the growing obesity epidemic worldwide resulting from sedentary lifestyles and unhealthy eating habits.
The Global Anti-Obesity Drug Market is estimated to be valued at US$ 2928.39 Mn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the anti-obesity drug market are ARJO, Etac AB, Medline Industries Inc., Guldmann Inc., Sunrise Medical Inc., Stryker Corporation, Winncare Group (Mangar Health), Joerns Healthcare Inc., Invacare Corporation, Baxter (Hill Rom Holding Inc.), Gainsborough Healthcare Group, and Savaria Corporation (Handicare Group AB), among others.
The growing demand for anti-obesity drugs can be attributed to the rising obesity rates worldwide along with increasing government initiatives to spread awareness about obesity management. As per WHO, over 650 million adults and 124 million children and adolescents were obese in 2016.
Rising R&D investments by key players to develop more efficacious and safer anti-obesity drugs is expected to fuel market growth over the forecast period. Players are focusing on developing drugs targeting novel pathways such as GLP-1,5-HT2C receptor agonism, and combined-mechanism approaches.
Market Trends
Herbal anti-obesity supplements gaining popularity - The popularity of herbal anti-obesity supplements is growing due to the perception of natural ingredients being safer than synthetic drugs. Plant-based supplements containing green tea, garcinia cambogia, and yerba mate extracts are gaining traction in the market.
Increasing uptake of digital therapeutics - Digital health solutions are being developed to complement anti-obesity drug therapy. These include wearable devices, apps, and online coaching programs focused on aspects like diet, exercise, medication schedules. Their integration aims to boost treatment adherence and efficacy.
Market Opportunities
Pediatric obesity management represents an area of opportunity. Over 340 million children and adolescents globally were overweight or obese in 2016 as per WHO projections. Currently, there are no FDA-approved weight loss medications for paediatric population.
Launch of novel anti-obesity drug candidates in late stages of development can drive high revenue generation potential. Players have a pipeline of candidates targeting pathways like serotonin, glucagon, and corticotrophin. Their successful approvals will open new avenues.
Impact of COVID-19 on Anti-Obesity Drug Market
The COVID-19 pandemic severely impacted the Anti-Obesity Drug Market Size initially due to lockdowns and social distancing norms implemented worldwide. During the lockdown period, people focused more on immunity booster supplements rather than weight loss supplements. With gymnasiums and fitness centers being closed, the scope of physical exercises also reduced significantly affecting the anti-obesity drug demand. However, post lockdowns when normalcy resumed partially, the anti-obesity drug market again picked up momentum as people renewed their focus on fitness and weight management. The demand for anti-obesity drugs increased from Q3 2020 onwards with relaxation in lockdown norms.
The major boost came from social media influencers promoting health and fitness especially during the pandemic times. Also, increasing prevalence of obesity related chronic diseases such as diabetes and cardiovascular issues drew more attention towards weight management in a healthy way using prescription anti-obesity drugs monitored by physicians. Teleconsultations also supported people in consulting doctors for anti-obesity drugs remotely. To capture the growing demand, market players focused on increasing awareness campaigns highlighting health benefits of maintaining normal body weight especially during pandemic times. They also strengthened their online sales and delivery channels for ensuring uninterrupted supplies of anti-obesity drugs.
Geographical regions with highest Anti-Obesity Drug Market value
North America accounted for the highest value share in the global anti-obesity drug market led by the United States. This is attributed to growing prevalence of obesity, availability of advanced weight management medicines, and high awareness levels about the health risks of being overweight. As per latest CDC report, over 40% of adults in the US are obese increasing their risk for diabetes, high blood pressure, heart diseases and other chronic ailments. Growing public and private initiatives to promote healthy lifestyle and related funding further boosted the anti-obesity drug adoption. Europe was the second largest market supported by favorable reimbursement policies, strategic product launches, and availability of generic anti-obesity drugs at lower costs.
Fastest growing region for Anti-Obesity Drug Market
Asia Pacific region is set to exhibit fastest growth during the forecast period in the global anti-obesity drug market. Rapid economic development, increasing affluence, changing food habits and sedentary lifestyles contributed to growing obesity epidemic in many Asian countries like China and India. This created a high potential demand for prescription and OTC anti-obesity drugs needed to control excessive weight gain in a healthy way. Supportive government initiatives to spread awareness about obesity risks and promote fitness are attracting major international players to enter Asian markets. High unmet needs, lack of stringent regulatory norms and availability of low cost generic drugs compared to developed nations open up opportunities for Asia Pacific to emerge as the fastest growing regional market.
Get more insights on: Anti-Obesity Drug Market
TheBusinessResearchCompany published its Antiobesity Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global antiobesity drugs market.
The report covers the antiobesity drugs market’s segments- peripherally acting anti-obesity drugs, centrally acting anti-obesity drugs, prescription drugs (Rx), OTC drugs, monotherapies, and polytherapies.Explore Complete Report https://www.thebusinessresearchcompany.com/report/antiobesity-drugs-global-market-reportAntiobesity Drugs Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 50+ geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Request to get the sample of this report https://www.thebusinessresearchcompany.com/sample.aspx?id=2449=smpThe pharmaceutical industry is witnessing an increase in the number of mergers and acquisitions among companies developing drugs for metabolic disorders such as obesity, diabetes and others.
This is a strategy of pharmaceutical companies to strengthen their drug portfolio in metabolic diseases and launch safe and effective drugs in the market.
